Dataset Information


A small-molecule compound identified through a cell-based screening inhibits JAK/STAT pathway signaling in human cancer cells.

ABSTRACT: Inappropriate activation of JAK/STAT signaling occurs with high frequency in human cancers and is associated with cancer cell survival and proliferation. Therefore, the development of pharmacologic STAT signaling inhibitors has therapeutic potential in the treatment of human cancers. Here, we report 2-[(3,5-bis-trifluoromethyl-phenyl)-hydroxy-methyl]-1-(4-nitro-phenylamino)-6-phenyl-1,2,4a,7a-tetrahydro-pyrrolo[3,4-b]-pyridine-5,7-dione (AUH-6-96) as a novel small-molecule inhibitor of JAK/STAT signaling that we initially identified through a cell-based high-throughput screening using cultured Drosophila cells. Treatment of Drosophila cells with AUH-6-96 resulted in a reduction of Unpaired-induced transcriptional activity and tyrosine phosphorylation of STAT92E, the sole Drosophila STAT homologue. In human cancer cell lines, AUH-6-96 inhibited both constitutive and interleukin-6-induced STAT3 phosphorylation. Specifically, in Hodgkin lymphoma L540 cells, treatment with AUH-6-96 resulted in reduced levels of tyrosine phosphorylated STAT3 and of the STAT3 downstream target gene SOCS3 in a dose- and time-dependent manner. In addition, AUH-6-96-treated L540 cells showed decreased expression of persistently activated JAK3, suggesting that AUH-6-96 inhibits the JAK/STAT pathway signaling in L540 cells by affecting JAK3 activity and subsequently blocking STAT3 signaling. Importantly, AUH-6-96 selectively affected cell viability only of cancer cells harboring aberrant JAK/STAT signaling. In support of the specificity of AUH-6-96 for inhibition of JAK/STAT signaling, treatment with AUH-6-96 decreased cancer cell survival by inducing programmed cell death by down-regulating the expression of STAT3 downstream target antiapoptotic genes, such as Bcl-xL. In summary, this study shows that AUH-6-96 is a novel small-molecule inhibitor of JAK/STAT signaling and may have therapeutic potential in the treatment of human cancers harboring aberrant JAK/STAT signaling.


PROVIDER: S-EPMC3646365 | BioStudies | 2008-01-01

REPOSITORIES: biostudies

Similar Datasets

2011-01-01 | S-EPMC3104254 | BioStudies
2013-01-01 | S-EPMC3998836 | BioStudies
2015-10-31 | E-GEOD-68562 | BioStudies
2021-01-01 | S-EPMC7828698 | BioStudies
2020-01-01 | S-EPMC7140109 | BioStudies
2020-01-01 | S-EPMC7507169 | BioStudies
2010-01-01 | S-EPMC3034357 | BioStudies
2016-01-01 | S-EPMC5053514 | BioStudies
2017-01-01 | S-EPMC5777778 | BioStudies
2004-01-01 | S-EPMC545791 | BioStudies